Last C$0.25 CAD
Change Today 0.00 / 0.00%
Volume 0.0
IMM On Other Exchanges
As of 12:04 PM 02/24/15 All times are local (Market data is delayed by at least 15 minutes).

immunotec inc (IMM) Snapshot

Previous Close
Day High
Day Low
52 Week High
06/3/14 - C$0.46
52 Week Low
09/23/14 - C$0.24
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for IMMUNOTEC INC (IMM)

Related News

No related news articles were found.

immunotec inc (IMM) Related Businessweek News

No Related Businessweek News Found

immunotec inc (IMM) Details

Immunotec Inc., a network marketing company, manufactures and sells natural health products and dietary supplements in Canada, the United States, Europe, Mexico, and other countries. The company’s principal products include Immunocal, a natural source of glutathione precursor cysteine for the maintenance of strong immune system; and Immunocal Platinum to reduce inflammation and body acidity. It also offers Pure Milk Calcium, a calcium supplement; Omega-3 + CoQ10 with Turmeric for the maintenance of heart and brain function; vitamin and mineral supplements with Chlorella; and Probiotics with Cranberry for the digestive system. In addition, the company provides Magistral, a natural liquid remedy that supports and maintains prostate health; PNT 200, a bioactive milk peptide for stress relief; Thermal Action tablets for weight-loss; and K-21 for energy production, growth, and nourishment functions. Further, it offers Xtra Sharp, an energy tonic; E-motion, an energy booster for maintaining physical stimulation and mental focus; concentrated cherry juice, skin perfecting cream, and toothpaste; and MiForm Transformation and Maintenance Kits, as well as meal replacement shakes and bars. The company sells its products through a network marketing system comprising independent distributors. Immunotec Inc. is headquartered in Vaudreuil-Dorion, Canada.

immunotec inc (IMM) Top Compensated Officers

Chief Executive Officer, Director and Chairma...
Total Annual Compensation: C$423.4K
Chief Financial Officer and Vice President
Total Annual Compensation: C$247.3K
Chief Operating Officer and Vice President
Total Annual Compensation: C$213.8K
Vice-President of Research & Development
Total Annual Compensation: C$206.5K
Vice President of Sales & Marketing
Total Annual Compensation: C$185.0K
Compensation as of Fiscal Year 2014.

immunotec inc (IMM) Key Developments

Immunotec Inc. Reports Consolidated Earnings Results for the Year Ended October 31, 2014

Immunotec Inc. reported consolidated earnings results for the year ended October 31, 2014. For the year, the company’s revenues were CAD 80,790,000 compared to CAD 54,771,000 a year ago. Operating loss was CAD 1,192,000 compared to operating income of CAD 1,035,000 a year ago. Net loss was CAD 2,692,000 or CAD 0.04 basic and diluted per share compared to net income of CAD 1,377,000 or CAD 0.02 basic and diluted per share a year ago. Adjusted EBITDA was CAD 5,018,000 compared to CAD 2,871,000 a year ago.

Immunotec Inc.'s New Study Demonstrates Immunocal(R) Supplementation Increases Muscle Strength in Elderly Adults

Immunotec Inc. announced important findings from this double-blind-randomized controlled study in elderly adults between the ages of 65 and 88. The results show that Immunocal(R) with statistical significance imparts a performance benefit of approximately 10% in muscle strength. This is very relevant for healthy aging, as the process is typically associated with a decrease in muscle strength that may contribute to disability in old age and to loss of quality of life. This trial was initiated by Immunotec Inc. The clinical trial application to run the trial was approved by Natural Health Products Directorate (NHPD) - a division of Health Canada responsible for evaluating the safety, efficacy and quality of natural health products (NHPs). This double-blind randomized controlled study recruited 99 sedentary non-frail elderly subjects aged between 65 and 88 years old, of which 76 were female and 23 male. Participants were randomly assigned into two groups. The experimental group consumed daily (20g) of a cysteine-rich whey protein isolate (Immunocal(R)) compared to daily (20g) casein-the control protein - over a period of 135 days (4.5 months). In addition, all subjects performed the same resistance training program 3 times per week over the 135 day period. Eighty-four (84) subjects completed the 135 day study period. Of these, 67 subjects (34 in the Immunocal(R) group and 33 in the control group) complied and used at least 80% of the study product and completed at least 80% of their training sessions. The key findings of the study showed increases in muscle strength in both groups after resistance training, however, significant additional increases were observed in muscle strength with addition of a cysteine rich whey protein (Immunocal(R)) versus casein by approximately 10% when expressed in kg per kg body weight (BW) and in kg per kg lean body mass (LBM) (p <0.05), hence the potential impact to perform daily tasks.

Immunotec Inc. Appoints Robert Raich as an Additional Member of its Board of Directors

Immunotec Inc. announced the appointment of Mr. Robert Raich as an additional member of its board of directors. Mr. Raich is a Senior Partner at the legal firm Spiegel Sohmer and has been with this firm since 1976. Mr. Raich also served as its Managing Partner from 1985 to 2011.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMM:CN C$0.25 CAD 0.00

IMM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMM.
View Industry Companies

Industry Analysis


Industry Average

Valuation IMM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 0.2x
Price/Book 1.5x
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.1x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOTEC INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at